The Safety and Efficacy of Fecal Microbiota Transplantation in the Treatment of Digestive Diseases and Non-digestive System Diseases Associated With Gastrointestinal Symptoms in the Gastrointestinal Tract.

Launched by SHANGHAI 10TH PEOPLE'S HOSPITAL · Jan 7, 2024

Keywords

ClinConnect Summary

This clinical trial is looking at a treatment called fecal microbiota transplantation (FMT), which involves transferring healthy bacteria from a donor's stool into a patient's gut. The goal is to see if this treatment can help not only with digestive diseases but also with other health issues that cause gastrointestinal symptoms. Researchers want to ensure that FMT is safe and effective while also trying to find the best ways to perform the procedure to improve results.

If you're considering joining this trial, you should be between the ages of 65 and 74 or 29 and 219 years old, and you need to be able to swallow a capsule or tolerate a small tube placed in your nose and down to your stomach. However, if you have certain serious gut issues or can't handle special nutrition through a feeding method, you may not be eligible. Participants in this study can expect to receive the FMT treatment and help contribute to important research that could benefit many people with similar health concerns.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Being able to tolerate a nasoenteric tube or swallow a capsule.
• Exclusion Criteria:
• • Intestinal barrier dysfunction. Inability to tolerate enteral nutrition.